ライフサイエンスコーパス: febuxostat

1 s Review, we focus on the clinical trials of febuxostat.

2 proved urate-lowering drugs, allopurinol and febuxostat.

3 , 76% taking 80 mg, and 94% taking 120 mg of febuxostat.

4 dence of the primary endpoint, on-treatment, febuxostat (172 patients [1.72 events per 100 patient-ye

5 rhea and dizziness were more frequent in the febuxostat 240 mg group.

6 lar frequency in the placebo (37%) and 40-mg febuxostat (35%) groups and with increased frequency in

7 Subjects received febuxostat (40 mg, 80 mg, 120 mg) or placebo once daily

8 in 53 percent of patients receiving 80 mg of febuxostat, 62 percent of those receiving 120 mg of febu

9 s: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febu

10 ts with impaired renal function treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11),

11 higher percentages of subjects treated with febuxostat 80 mg (48%), 120 mg (65%), and 240 mg (69%) a

12 r (480 micromol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) onc

13 nction were randomized to receive once-daily febuxostat (80 mg, 120 mg, or 240 mg), allopurinol (300

14 The approval of febuxostat, a non-purine-analogue inhibitor of xanthine

15 er therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibi

16 udy was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine

17 Febuxostat, a novel nonpurine selective inhibitor of xan

18 Febuxostat, a novel xanthine oxidase inhibitor, represen

19 ersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.

20 lopurinol-febuxostat sequential therapy; and febuxostat-allopurinol sequential therapy.

21 as 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg of f

22 Febuxostat and allopurinol are urate-lowering therapies

23 t-related adverse events were similar in the febuxostat and placebo groups.

24 tat, 62 percent of those receiving 120 mg of febuxostat, and 21 percent of those receiving allopurino

25 tat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those receiving allopurino

26 A new xanthine oxidase inhibitor, febuxostat, and pegylated uricases are in clinical trial

27 and 66 percent in those receiving 120 mg of febuxostat, as compared with 50 percent in those receivi

28 allopurinol (at the optimised dose) or start febuxostat at 80 mg/day, increasing to 120 mg/day if nec

29 Febuxostat, at a daily dose of 80 mg or 120 mg, was more

30 study assessing the cardiovascular safety of febuxostat compared with allopurinol.

31 rios were investigated: fixed dose (80 mg of febuxostat daily, 0.80 success rate; 300 mg of allopurin

32 cess rate) and dose escalation (</=120 mg of febuxostat daily, 0.82 success rate; </=800 mg of allopu

33 Similarly, febuxostat dramatically lowered plasma and tissue UA and

34 ions at baseline and after PUA lowering with febuxostat (FBX) for 8 weeks.

35 e (Dec 31, 2019), 189 (6.2%) patients in the febuxostat group and 169 (5.5%) in the allopurinol group

36 discontinued in 973 (32.4%) patients in the febuxostat group and 503 (16.5%) patients in the allopur

37 allopurinol group (P=0.003) or the low-dose febuxostat group discontinued the study.

38 More patients in the high-dose febuxostat group than in the allopurinol group (P=0.003)

39 opurinol (P<0.001 for the comparison of each febuxostat group with the allopurinol group).

40 In the febuxostat group, 222 (7.2%) of 3063 patients died and 1

41 Four of the 507 patients in the two febuxostat groups (0.8 percent) and none of the 253 pati

42 ith increased frequency in the higher dosage febuxostat groups (43% taking 80 mg; 55% taking 120 mg).

43 0.31 for the comparison between the combined febuxostat groups and the allopurinol group).

44 -mg, 44% in the 80-mg, and 59% in the 120-mg febuxostat groups.

45 e oxidase inhibitors such as allopurinol and febuxostat have been the mainstay urate-lowering therapy

46 Patients for whom allopurinol or febuxostat is a suitable initial urate-lowering treatmen

47 herapies such as urate synthesis inhibitors (febuxostat is already FDA approved and BCX4208 is in dev

48 Febuxostat is non-inferior to allopurinol therapy with r

49 Studies of allopurinol and febuxostat lowering of serum urate have once again raise

50 Finally, a potent UA synthesis inhibitor, febuxostat, mitigated asthma phenotypes that were caused

51 At all doses studied, febuxostat more effectively lowered and maintained serum

52 allocated to receive allopurinol (n=3065) or febuxostat (n=3063).

53 whole-body pharmacologic inhibition of XOR (febuxostat) on obesity-induced insulin resistance/dyslip

54 ere evaluated: no treatment; allopurinol- or febuxostat-only therapy; allopurinol-febuxostat sequenti

55 that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for acute gout attack

56 Treatment with febuxostat resulted in a significant reduction of sUA le

57 Dose-escalation allopurinol-febuxostat sequential therapy is cost-effective compared

58 s ratios of dose escalation with allopurinol-febuxostat sequential therapy remained lower than the wi

59 Dose-escalation allopurinol-febuxostat sequential therapy was more costly but more e

60 nol- or febuxostat-only therapy; allopurinol-febuxostat sequential therapy; and febuxostat-allopurino

61 r gout flares, which were more frequent with febuxostat than with allopurinol.

62 concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a

63 Febuxostat therapy was safe and well tolerated.

64 Greater proportions of febuxostat-treated patients than placebo-treated patient

65 Last, febuxostat treatment decreased complement activation bio

66 Nevertheless, both allopurinol and febuxostat treatment has sustained the hypothesis that h

67 The hazard ratio (HR) for febuxostat versus allopurinol in a Cox proportional haza

68 , blinded-endpoint, non-inferiority trial of febuxostat versus allopurinol in patients with gout in t

69 xostat vs. allopurinol; P=0.23 for 120 mg of febuxostat vs. allopurinol).

70 xostat vs. allopurinol; P=0.16 for 120 mg of febuxostat vs. allopurinol).

71 e receiving allopurinol (P=0.08 for 80 mg of febuxostat vs. allopurinol; P=0.16 for 120 mg of febuxos

72 e receiving allopurinol (P=0.99 for 80 mg of febuxostat vs. allopurinol; P=0.23 for 120 mg of febuxos